莫西沙星治疗中青年耐多药肺结核的疗效

Curative effect of moxifloxacin in the treatment of young multi-drug resistant pulmonary tuberculosis

目的观察莫西沙星与左氧氟沙星辅助治疗中青年耐多药肺结核(MDR-PTB)的效果,并评价两药的用药安全性。方法将106例中青年MDR-PTB患者随机分为两组,在常规抗结核药物治疗基础上,A组(n=53)给予莫西沙星,B组(n=53)给予左氧氟沙星,两组均持续治疗12个月;比较两组的效果和不良反应。结果 A组的临床总有效率、痰菌转阴率、空洞关闭率均显著高于B组(P<0.05);两组的不良反应率无显著差异(P>0.05)。结论莫西沙星辅助治疗中青年耐多药肺结核的效果更好,不良反应率更低,更有效更安全。

Objective To compare the curative effect of moxifloxacin and levofioxacin in the treatment of young multi-drug resistant pulmonary tuberculosis, and to evaluate the safety of the two drugs. Methods 106 young patients with MDR-PTB were randomly divided into two groups. All patients were given conventional anti tuberculosis drug treatment, the group A （ n = 53 ） was additionally treated with moxifloxacin, and the group B （ n = 53 ） was ad- ditionally treated with levofloxacin for 12 months. Their curative effect and adverse reactions were compared between the two groups. Results The total efficiency, the sputum negative conversion rate, and the cavity closure rate were significantly higher in the group A than in the group B （ P 〈 0. 05 ）. There was no significant difference in adverse re- actions between the two groups （P 〉 0. 05）. Conclusion Moxifloxacin has the advantages of better efficacy, lower adverse reactions and higher safety in treatment of young multi-drug resistant pulmonary tuberculosis.